Grace E. VanNoy

Grace E. VanNoy

Auto-generated profile, based on publicly available information

Grace E. VanNoy

Program in Medical and Population Genetics, Broad Institute of MIT and Harvard

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2022 in Human Mutation
Verified
Journal Article
Closed access
PDF file
YGYoel Gofin
Yoel Gofin
TWTianyun Wang
Tianyun Wang
MGMadelyn A. Gillentine
Madelyn A. Gillentine
TSTiana Scott
Tiana Scott
ABAliska M. Berry
Aliska M. Berry
DSDaryl A. Scott
Daryl A. Scott

8 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
YCYuyang Chen
Yuyang Chen
RDRuebena Dawes
Ruebena Dawes
HKHyung Chul Kim
Hyung Chul Kim
SSSarah L Stenton
Sarah L Stenton
SWSusan Walker
Susan Walker
NWNicola Whiffin
Nicola Whiffin
Around 60% of individuals with neurodevelopmental disorders (NDD) remain undiagnosed after comprehensive genetic testing, primarily of protein-coding genes 1 . Increasingly, large genome-sequenced cohorts are improving our ability to discover new diagnoses in the non-coding genome. Here, we identify the non-coding RNA RNU4-2 as a novel syndromic NDD gene. RNU4-2 encodes the U4 small nuclear RNA (snRNA), which is a critical component of the U4/U6.U5 tri-snRNP complex of the major spliceosome 2 . We identify an 18 bp region of RNU4-2 mapping to two structural elements in the U4/U6 snRNA duplex (the T-loop and Stem III) that is severely depleted of variation in the general population, but in which we identify heterozygous variants in 119 individuals with NDD. The vast majority of individuals (77.3%) have the same highly recurrent single base-pair insertion (n.64_65insT). We estimate that variants in this region explain 0.41% of individuals with NDD. We demonstrate that RNU4-2 is highly expressed in the developing human brain, in contrast to its contiguous counterpart RNU4-1 and other U4 homologs, supporting RNU4-2 ’s role as the primary U4 transcript in the brain. Overall, this work underscores the importance of non-coding genes in rare disorders. It will provide a diagnosis to thousands of individuals with NDD worldwide and pave the way for the development of effective treatments for these individuals.

4 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
SSSarah L. Stenton
Sarah L. Stenton
MOMelanie O’leary
Melanie O’leary
GLGabrielle Lemire
Gabrielle Lemire
GVGrace E. VanNoy
Grace E. VanNoy
SDStephanie DiTroia
Stephanie DiTroia
AOAnne O’donnell-Luria
Anne O’donnell-Luria
Background: A major obstacle faced by rare disease families is obtaining a genetic diagnosis. The average “diagnostic odyssey” lasts over five years, and causal variants are identified in under 50%. The Rare Genomes Project (RGP) is a direct-to-participant research study on the utility of genome sequencing (GS) for diagnosis and gene discovery. Families are consented for sharing of sequence and phenotype data with researchers, allowing development of a Critical Assessment of Genome Interpretation (CAGI) community challenge, placing variant prioritization models head-to-head in a real-life clinical diagnostic setting. Methods: Predictors were provided a dataset of phenotype terms and variant calls from GS of 175 RGP individuals (65 families), including 35 solved training set families, with causal variants specified, and 30 test set families (14 solved, 16 unsolved). The challenge tasked teams with identifying the causal variants in as many test set families as possible. Ranked variant predictions were submitted with estimated probability of causal relationship (EPCR) values. Model performance was determined by two metrics, a weighted score based on rank position of true positive causal variants and maximum F-measure, based on precision and recall of causal variants across EPCR thresholds. Results: Sixteen teams submitted predictions from 52 models, some with manual review incorporated. Top performing teams recalled the causal variants in up to 13 of 14 solved families by prioritizing high quality variant calls that were rare, predicted deleterious, segregating correctly, and consistent with reported phenotype. In unsolved families, newly discovered diagnostic variants were returned to two families following confirmatory RNA sequencing, and two prioritized novel disease gene candidates were entered into Matchmaker Exchange. In one example, RNA sequencing demonstrated aberrant splicing due to a deep intronic indel in ASNS , identified in trans with a frameshift variant, in an unsolved proband with phenotype overlap with asparagine synthetase deficiency. Conclusions: By objective assessment of variant predictions, we provide insights into current state-of-the-art algorithms and platforms for genome sequencing analysis for rare disease diagnosis and explore areas for future optimization. Identification of diagnostic variants in unsolved families promotes synergy between researchers with clinical and computational expertise as a means of advancing the field of clinical genome interpretation.

7 August 2022 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
LKLaura Keehan
Laura Keehan
IHIsabel Haviland
Isabel Haviland
YGYoel Gofin
Yoel Gofin
LSLindsay C. Swanson
Lindsay C. Swanson
CAChristelle Moufawad El Achkar
Christelle Moufawad El Achkar
UNUndiagnosed Diseases Network
Undiagnosed Diseases Network

21 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
LHLaurel Hiatt
Laurel Hiatt
BWBen Weisburd
Ben Weisburd
EDEgor Dolzhenko
Egor Dolzhenko
GVGrace E. VanNoy
Grace E. VanNoy
EKEdibe Nehir Kurtas
Edibe Nehir Kurtas
HDHarriet Dashnow
Harriet Dashnow
Approximately 3% of the human genome consists of repetitive elements called tandem repeats (TRs), which include short tandem repeats (STRs) of 1–6bp motifs and variable number tandem repeats (VNTRs) of 7+bp motifs. TR variants contribute to several dozen mono- and polygenic diseases but remain understudied and “enigmatic,” particularly relative to single nucleotide variants. It remains comparatively challenging to interpret the clinical significance of TR variants. Although existing resources provide portions of necessary data for interpretation at disease-associated loci, it is currently difficult or impossible to efficiently invoke the additional details critical to proper interpretation, such as motif pathogenicity, disease penetrance, and age of onset distributions. It is also often unclear how to apply population information to analyses. We present STRchive (S-T-archive, http://strchive.org/ ), a dynamic resource consolidating information on TR disease loci in humans from research literature, up-to-date clinical resources, and large-scale genomic databases, with the goal of streamlining TR variant interpretation at disease-associated loci. We apply STRchive —including pathogenic thresholds, motif classification, and clinical phenotypes—to a gnomAD cohort of ∼18.5k individuals genotyped at 60 disease-associated loci. Through detailed literature curation, we demonstrate that the majority of TR diseases affect children despite being thought of as adult diseases. Additionally, we show that pathogenic genotypes can be found within gnomAD which do not necessarily overlap with known disease prevalence, and leverage STRchive to interpret locus-specific findings therein. We apply a diagnostic blueprint empowered by STRchive to relevant clinical vignettes, highlighting possible pitfalls in TR variant interpretation. As a living resource, STRchive is maintained by experts, takes community contributions, and will evolve as understanding of TR diseases progresses.

1 August 2020 in Kidney International Reports
Verified
Journal Article
Open access
GVGrace E. VanNoy
Grace E. VanNoy
MWMonica Wojcik
Monica Wojcik
CGCasie A. Genetti
Casie A. Genetti
TMThomas E. Mullen
Thomas E. Mullen
PAPankaj B. Agrawal
Pankaj B. Agrawal
DSDeborah R. Stein
Deborah R. Stein